Sun Pharma Q2 FY27 Earnings Report

Sales: INR 16,100 crore (+11.8% YoY); Adjusted PAT: INR 3,162 crore.

Reader Takeaway: Strong Indian market share and growth provide a buffer against US generic cyclical declines and product-specific slowdowns.

What just happened

Sun Pharmaceutical Industries Ltd released its Q2 FY27 financial results, highlighting a 11.8% increase in consolidated sales to INR 16,100 crore. The company reported a reported net profit of INR 1,989 crore and an adjusted net profit of INR 3,162 crore. EBITDA stood at INR 4,744 crore, reflecting a 29.3% margin, with management citing the high base effect from lenalidomide sales in the prior-year quarter as a key factor in margin compression.

Why this matters

The company’s performance highlights a two-speed business model. The India business remains a cornerstone, with sales of INR 5,552 crore and 17.3% growth, significantly outpacing the broader industry's 1.8% growth rate. Conversely, the US market saw an 8.2% YoY decline, reflecting the volatility of generic product cycles. The firm’s ability to lean on its #1 domestic position is providing the necessary stability as it manages ongoing transitions in its innovative medicine portfolio.

Segment Performance

• India Business: Secured 17.3% growth with an 8.6% overall market share.
• US Business: Sales reached USD 455 million, showing a 6.5% sequential improvement despite the YoY decline.
• Innovative Medicines: Contributed 21.1% to total sales, totaling USD 356 million, though growth in the Ilumya product slowed during the period.

Regulatory and Operational Updates

Sun Pharma has voluntarily initiated a temporary manufacturing pause for 11 ophthalmic products at its Assam facility. The company is actively coordinating with Indian regulators to implement remedial actions. Additionally, the acquisition of Organon is progressing toward an expected Q4 FY27 closure, with most regulatory hurdles already cleared.

Risks to watch

The primary concern remains the dependency on US generic cycles, which caused the observed YoY decline in US sales. Investors should also monitor the recovery trajectory of the innovative medicines segment, specifically Ilumya, and any potential supply constraints arising from the Assam plant manufacturing pause.

Context metrics

• Net Cash Position: USD 3.3 billion.
• R&D Spend: INR 778 crore (4.8% of sales).
• H1 Sales: INR 31,284 crore.